Policy & Regulation
Medincell partner Teva secures FDA approval for monthly schizophrenia treatment
9 October 2026 - French biopharmaceutical company Medincell S.A. (Euronext Paris: MEDCL) announced on Friday that its partner Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd...
Alumis reports new Phase 3 data showing sustained skin clearance with envudeucitinib
9 October 2026 - US biopharmaceutical company Alumis Inc. (NASDAQ: ALMS) on Friday released new Phase 3 data from its ONWARD1, ONWARD2 and ONWARD3 studies of envudeucitinib in moderate-to-severe plaqu...
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
9 October 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that the US Food and Drug Administration (FDA) has approved Tecentriq (...
Sophos IRB and ALCMI partner to support lung cancer research
9 October 2026 - Sophos IRB Inc, an independent, oncology-focused central institutional review board, announced on Thursday a strategic partnership with the Addario Lung Cancer Medical Institute (ALCM...
Innovent Biologics achieves primary study endpoint for inactive thyroid eye disease antibody
9 October 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Thursday that its recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, SYCUME (...
argenx reports positive Phase 2 results for FB102 in coeliac disease
8 October 2026 - European immunology company argenx SE (EBR & NASDAQ: ARGX) on Thursday reported positive top-line results from a Phase 2 study of FB102, a first-in-class CD122 inhibitor, in adult...